Download PDF
Rofo 2014; 186(07): E1
DOI: 10.1055/s-0035-1553365
Erratum
© Georg Thieme Verlag KG Stuttgart · New York

Application of Extracellular Gadolinium-based MRI Contrast Agents and the Risk of Nephrogenic Systemic Fibrosis

Anwendung von extrazellulären gadoliniumhaltigen MR-Kontrastmitteln und Risiko der Nephrogenen Systemischen Fibrose
J. T. Heverhagen
1   University Institute of Diagnostic, Interventional and Pediatric Radiology, Inselspital, University Hospital Bern, Bern
,
G. A. Krombach
2   Diagnostic and Interventional Radiology, University Hospital Giessen, Justus Liebig University Giessen, Gießen
,
E. Gizewski
3   Department for Neuroradiology, Innsbruck Medical University, Innsbruck
› Author Affiliations
Further Information

Publication History

Publication Date:
02 July 2015 (online)

Also available at
   Permissions and Reprints

Erratum (2.7.2015) to: “Application of Extracellular Gadolinium-based MRI Contrast Agents and the Risk of Nephrogenic Systemic Fibrosis. Heverhagen JT et al. Fortschr Röntgenstr 2014; 186: 661 – 669”

We apologize for a translation error in the English version of this article. The sentence “The result is the following groups: gadopentetate dimeglumine, gadodiamide, gadoversetamide belong to Group I “Agents associated with the greatest number of NSF cases; (...)” was corrected with the correct term “gadopentetate”.”